We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+43.81%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$232M
AUM Growth
-$77.7M
(-25%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-58.95%
Top 10 Holdings %
Top 10 Hldgs %
92.15%
Holding
21
New
2
Increased
5
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arbutus Biopharma
ABUS
|
+$5.99M |
| 2 |
Cytokinetics
CYTK
|
+$5.14M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$2.08M |
| 4 |
SI-BONE Inc
SIBN
|
+$1.84M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$1.35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$68.7M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$19.6M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$17.8M |
| 4 |
OPTN
OptiNose
OPTN
|
+$11.8M |
| 5 |
Alector
ALEC
|
+$9.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
| $36.3M | 15.66% |
1,501,400
+100,500
| +7% | +$2.08M |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $34.2M | 14.78% |
403,217
-75,000
| -16% | -$5M |
|
3
Insmed
INSM
$22.4B
| $34.1M | 14.73% |
1,429,518
| – | – |
|
|
4
Cytokinetics
CYTK
$10.6B
| $25.5M | 10.98% |
2,398,970
+500,000
| +26% | +$5.14M |
|
5
Fulcrum Therapeutics
FULC
$241M
| $25M | 10.77% |
1,500,000
-187,500
| -11% | -$1.79M |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $19M | 8.19% |
260,370
+22,184
| +9% | +$1.35M |
|
7
Voyager Therapeutics
VYGR
$181M
| $11.6M | 5% |
830,565
| – | – |
|
|
8
Arbutus Biopharma
ABUS
$847M
| $10.3M | 4.44% |
+3,705,128
| New | +$5.99M |
|
|
9
Ascendis Pharma A/S
ASND
$16.5B
| $9.6M | 4.14% |
68,981
-176,443
| -72% | -$19.6M |
|
|
OPTN
10
DELISTED
OptiNose
OPTN
| $8.03M | 3.46% |
58,051
-91,149
| -61% | -$11.8M |
|
|
11
SI-BONE Inc
SIBN
$818M
| $6.63M | 2.86% |
308,183
+102,562
| +50% | +$1.84M |
|
|
12
Alector
ALEC
$169M
| $6.09M | 2.63% |
353,462
-582,909
| -62% | -$9.91M |
|
|
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
| $4.54M | 1.96% |
2,315,016
+254,748
| +12% | +$957K |
|
14
Kura Oncology
KURA
$793M
| $935K | 0.4% |
+68,000
| New | +$1.01M |
|
15
Rhythm Pharmaceuticals
RYTM
$7.31B
| – | – |
-234,482
| Closed | -$5.06M |
|
|
ORTX
16
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| – | – |
-55,770
| Closed | -$6.63M |
|
|
AERI
17
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-100,500
| Closed | -$1.93M |
|
|
AERI
18
PUT
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-100,500
| Closed | -$1.93M |
|
|
TPTX
19
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| – | – |
-1,826,374
| Closed | -$68.7M |
|
|
IMMU
20
DELISTED
Immunomedics Inc
IMMU
| – | – |
-367,636
| Closed | -$4.88M |
|
|
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-425,794
| Closed | -$17.8M |
|
Similar funds
BCM
ICMM
AG
FL
EA
PVM
MFA
TCM
Foresite Capital Management IV's Q4 2019 Portfolio in Review
As of Q4 2019, Foresite Capital Management IV held 21 positions worth $232M, down 25% from $309M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Foresite Capital Management IV withdrew a net $137M in Q4 2019, closing 7 positions and reducing 5 holdings. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $68.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 81% a quarter earlier.
Against the trend, Foresite Capital Management IV opened a new position in Arbutus Biopharma worth $10.3M.
- Foresite Capital Management IV's largest Q4 2019 buy was Arbutus Biopharma: 3,705,128 shares worth $10.3M.
- Foresite Capital Management IV added most to Cytokinetics in Q4 2019, an estimated $5.14M increase.
- Foresite Capital Management IV's biggest Q4 2019 reduction was Ascendis Pharma A/S, cutting an estimated $19.6M.
- Foresite Capital Management IV fully exited Turning Point Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $68.7M.
- Foresite Capital Management IV's ten largest holdings make up 92% of its $232M portfolio in Q4 2019.
- Foresite Capital Management IV opened 2 new positions and closed 7 in Q4 2019.
- Foresite Capital Management IV's portfolio value fell 25% quarter-over-quarter to $232M.
Based on Foresite Capital Management IV's 13F filing for Q4 2019, filed 14 Feb 2020.